NFXF Blog

Learn how you can help us educate more clinicians about the Fragile X premutation, with a special emphasis on raising awareness for FXPOI, in 2026.

Meet Will, who lives with Fragile X syndrome and participates in research studies. Learn how your gift on Giving Tuesday will help grow the future of Fragile X research.

This research looks at how a child’s level of intellectual disability (ID) — meaning how much their thinking and learning abilities are affected — relates to the types of behavioral challenges they experience if they have Fragile X syndrome (FXS).

CONNECTA Therapeutics is taking a new approach to Fragile X syndrome treatment by boosting the brain’s natural ability to reconnect and adapt.

Harmony Biosciences recently announced results from its Phase 3 RECONNECT study of ZYN002, a cannabidiol (CBD) gel being tested for Fragile X syndrome.

Bowen’s FX Therapeutics, a company with roots in the Fragile X community, is advancing efforts toward a future protein replacement therapy.

The NFXF joined researchers and clinicians at the 6th International Conference on Fragile X Premutation Associated Conditions in Italy to advance understanding of FXTAS, FXPOI, and related conditions, update treatment recommendations, and strengthen global Fragile X collaboration.

Congratulations to 2025’s three NFXF Summer Scholars. Meet Susana Lopez-Ignacio, Tanvi Kamra, and Shelby Dauterman!

On Tuesday, July 22, the Rhode Island State House held a special lighting called Lighting the Way for Fragile X in honor of National Fragile X Awareness Day. And, of course, all of the Little Rhody Warriors were there!